Iovance Biotherapeutics, Inc. reported that it updated its corporate presentation on June 30, 2026, according to a Form 8-K filed on July 2, 2026. The company said the revised presentation is intended for use in meetings and presentations at healthcare conferences, and with analysts, current stockholders, and other audiences. The filing was made under Item 8.01, “Other Events,” which companies commonly use to disclose information they believe may be of interest to investors but that does not fall under more specific Form 8-K categories. Iovance did not report a financing, acquisition, executive change, securities issuance, insider transaction, or material agreement in this filing. No share counts, transaction prices, option grants, vesting terms, or ownership changes were disclosed. The updated presentation was filed as Exhibit 99.1 and is described as “Iovance Biotherapeutics, Inc., Corporate Presentation – June 2026.” Because the text provided does not include the contents of that presentation, the filing itself only confirms that the company has refreshed the materials it uses to communicate its corporate strategy, pipeline, business updates, and related investor-facing information. The report was signed on behalf of Iovance by Frederick G. Vogt, Ph.D., J.D., who is identified as Interim CEO and President, and General Counsel. The filing matters primarily because updated investor presentations can signal how management is currently framing the company’s business outlook and priorities, even though this particular Form 8-K does not announce a discrete corporate transaction or insider action.